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Apart from conjunctival involvement which is the most well-known ocular
manifestation of coronavirus infectious disease 2019 (COVID-19), there are
multiple reports of the involvement of other ocular structures by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We comprehensively
reviewed PubMed, Scopus, Embase, and Google Scholar for available
evidence regarding COVID-19 various ocular manifestations, with special
focus on less known and unusual ocular findings. We then categorized the
findings based on the parts of the eye which was involved. In anterior
sections of the eye, the involvement of the eyelid (tarsadenitis), conjunctiva
and cornea (follicular conjunctivitis, pseudomembranous conjunctivitis, and
keratoconjunctivitis), episclera (nodular episcleritis), uvea (anterior uveitis) were
reported. Also, third, fourth, and sixth nerve palsy, retinal vasculitis, retinal optical
coherence tomography (OCT) changes (hyper-reflective lesions and increased
retinal nerve fiber layer thickness [RNFLT]), optic neuritis, papillophlebitis, Miller
Fisher syndrome, posterior reversible leukoencephalopathy (PRES), ophthalmic
artery and central retinal artery occlusion, and polyneuritis cranialis were
reported in different studies. Postmortem evaluation of COVID-19 patients
detected no viral RNA in different anterior and posterior segments of the eyes.
However, another study revealed a 21.4% positivity of the retinal biopsies of dead
patients. The results of this study can help ophthalmologists to be vigilant when
they see these findings in a suspected case of COVID-19. In addition, wearing
face masks and protective goggles or eye shields are recommended, especially
in high risk contacts.
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INTRODUCTION
Since December 2019, coronavirus has caused
more than 990,000 deaths and contamination
of more than 32.7 million people globally till
September 27, 2020.[1] Coronavirus disease 2019
(COVID-19) can be transmitted directly through
person to person contacts via droplets released
during sneezing or coughing. Indirect transmission
of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) through surface contamination
can be regarded as the second way of getting
infected.[2–4] In addition, SARS-CoV-2 has been
detected in tears and conjunctival secretions of
infected people.[5] Therefore, adhering to personal
hygiene principles is a fundamental part of COVID-
19 prevention, especially for healthcare workers.
Ophthalmologists are at high risk of contracting
COVID-19 due to their close contact with
the patients during routine ophthalmologic
exams such as slit lamp examinations and
direct ophthalmoscopy.[6] Also, the patients’
prolonged stay at ophthalmology clinics for
multiple ophthalmology examinations imposes
ophthalmologists and other patients at increased
risk of COVID-19.[7] A recent study revealed a
high probability of contamination of environmental
surfaces of ophthalmology clinics.[8] Ocular
presentations of COVID-19 usually occur about
two weeks after the first symptoms. However, it
can be the presenting finding of newly diagnosed
COVID-19 patients, especially when the virus
enters from the eye mucosa.[9] Consequently,
knowing the latest presentations of COVID-19
is crucial for every ophthalmologist. It helps
ophthalmologists to consider COVID-19 as a
possible causative agent when they see these
findings.
Like SARS-CoV, angiotensin-converting enzyme
2 (ACE 2) receptor is the mediator of SARS-
CoV-2 for entering the host cells.[10–12] ACE 2
receptor is expressed in different human tissue,
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including the pulmonary system, proximal tubule
of kidney and bladder urothelium, myocardial
cells, esophagus, and ileum.[13] In the eye, ACE 2
receptor expression is reported in the conjunctiva,
limbus, cornea, retina, and aqueous humor.[14–17] It
was thought earlier that COVID-19 only involves
conjunctiva, cornea, and tear. However, recent
studies have revealed the involvement of the other
eye structures, such as eyelid, episcleral, and
retina. Therefore, we gathered available data about
ocular manifestations of COVID-19, focusing on
recently reported manifestations.
METHODS
We systematically searched four databases,
including Medline (Pubmed), Scopus, Embase,
and Google Scholar for articles about ocular
manifestations of COVID-19. We used the
following keywords for searching the databases
: (“coronavirus” OR “covid-19” OR “2019-ncov”
OR “sars-cov-2”) AND (“ocular” OR “eye” OR
“cornea” OR “conjunctivitis” OR “conjunctiva” OR
“conjunctival” OR “congestion” OR “uvea” OR
“uveitis” OR “retina” OR “retinal” OR “retinitis” OR
“optic” OR “lens” OR “chemosis” OR “blepharitis”
OR “ophthalmic” OR “ophthalmologic” OR
“ophthalmoplegia” OR “ophthalmoparesis” OR
“nerve palsy”). We also searched the references of
the included studies for more relevant articles. The
primary search was done on June 19, 2020 and
was updated on August 27, 2020. The inclusion
criteria were original articles about the ocular
manifestations of COVID-19 patients. Case reports
and case series, letters, and editorials were also
included. Studies without any information about
ocular manifestations of COVID-19 were excluded.
Also, some of the studies reporting duplicate
and repeated well-known ocular manifestations
of COVID-19 were excluded, and the main focus
was put on the less reported ophthalmologic
presentations. Included studies were categorized
in this study and divided based on the involved
part of the eye.
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We used Joanna Briggs Institute ( JBI)’s critical
appraisal tool[18] to assess the risk of bias of the
included studies. The scores were calculated
as percentages and studies with scores of
>60% and <30% of total scores were regarded
as low- and high risk of bias, respectively.
Title and abstract screening, data extraction
and risk of bias assessment were done by
two authors (AR and MA) independently and
disagreements were checked by another author
(RR).
As shown in Figure 1, a total of 5,288 studies
were initially found after searching the databases
according to the aforementioned search strategy.
After title and abstract screening, 85 studies
were chosen for full-text evaluation. Finally, 40
studies were matched with our inclusion criteria
to enter the study. Conjunctival involvement and
conjunctival and tear COVID-19 PCR positivity
have been reported before. Furthermore, there are
several reports of some rare ocular manifestations
of COVID-19, which are unfamiliar to many
ophthalmologists and physicians. Therefore,
we summarized the conjunctival findings part
in our study and focused more on the less
reported and less known ocular manifestations.




A woman from Wuhan, China, who presented with
lower eyelid swelling, pain, and tenderness in the
lateral canthus of the right eye was diagnosed
as acute tarsadenitis. The patient had visited her
parents who had tested positive for COVID-19
one day before the onset of these manifestations.
Along with the resolution of tarsadenitis, the
patient developed subconjunctival hemorrhage.
Radiologic and PCR test results were in favor
of COVID-19 infection.[19]Another study reported
multiple cases of chalazion in three ICU nurses
and ten additional cases in a hospital in Paris.[20]
PCR results of the ICU nurses were negative.
Because of the role of bacterial infection in
eyelid disorders such as blepharitis andmeibomian
gland diseases,[21, 22] it is far from the mind that
SARS-CoV-2 itself could be responsible for the
observed tarsadenitis and chalazion. However,
it is thought that the cluster of chalazion was
mainly due to the occupational conditions while
managing COVID-19 patients. Firstly, prolonged
use of eye goggles and the following reduced
eye blinking can facilitate the evaporation of the
tear film and hardening of the meibomian gland
secretions. Secondly, the use of some disinfectants
for cleaning eye shields can be irritating for the
eyes.[20] Thirdly, due to the role of blood supply
on fat synthesis, we hypothesize that impaired
blood flow due to the hypercoagulable state in
COVID-19 patients[23] can change the composition
of meibomian gland secretions and predispose the
eyes to bacterial infection and followingmeibomian
gland infection and tarsadenitis.[24] Summary of the
findings of eyelid, ocular surface, uvea, episclera,
and ocular motor nerves are presented in Table
1.
Ocular surface: conjunctiva and cornea
Hyperemia, epiphora, increased secretion,
chemosis, and follicular conjunctivitis are the
main symptoms of conjunctival involvement
with SARS-CoV-2.[25] Based on the “Report of the
WHO−China Joint Mission on Coronavirus Disease
2019 (COVID−19),” conjunctival congestion
occurs in about 0.8% of COVID-19 patients.[26]
However, other studies showed higher rates.
In Chen et al study, about 5% of COVID-19
patients had conjunctival congestions, 15% of
whom as the initial presentations. Another study
showed that 3.1% of COVID-19 patients presented
with conjunctivitis, 0.7% of whom as the first
symptom of the disease.[27] A high prevalence of
conjunctivitis was reported to be 32% in Wu et al’s
study.[9] A meta-analysis stated that the overall
prevalence of conjunctivitis among COVID-19
patients is about 1.1%. It also showed that this
prevalence was 0.7% in non-severe cases and 3%
in severe ones.[28] Common ocular symptoms of
conjunctival congestion are increased conjunctival
secretion, ocular pain, photophobia, dry eye,
and tearing. It was also shown that conjunctival
congestion is higher in patients with more hand–
eye contact.[29]
In another study, a patient presented with
conjunctival hyperemia, secretion, follicles,
petechiae, tarsal hemorrhages, and chemosis
with easily removed yellowish membrane on
the tarsal conjunctiva of the lower lids. He was
diagnosed as pseudomembranous conjunctivitis
and punctate keratitis.[30]
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Figure 1. PRISMA flow chart of the screened and assessed articles.
Positive SARS-CoV-2 detection in conjunctival
samples or ocular secretions has been reported in
several studies.[31, 32] A systematic review showed
that conjunctival/tear PCR samples were positive in
about 2% of COVID-19 patients.[27] Different studies
revealed variation in positive PCR rate from 3 to
16%, with an average of 5.8%.[33]
These variations may be due to the
technical problems during collecting, keeping,
and handling of the specimen, low viral
load in the conjunctival secretion of some
participants, and also the difference between
the severity of the disease in different
studies.[34, 35]
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Reminding the experience with SARS-CoV-
1 increased transmission during unprotected
eye contacts,[36] and possible transmission of
SARS-CoV-2 through the conjunctiva, wearing
protective goggles should become routine among
healthcare workers with high risk contacts.[37] It
should be kept in mind that keratoconjunctivitis
can be the initial manifestation of patients
with COVID-19 infection.[38] Therefore, first-line
healthcare providers should ask questions
regarding other manifestations of COVID-19
like fever and cough and a history of suspicious
contact in patients presenting with a red eye.
It is also revealed that conjunctival/tear PCR
samples may be positive in some patients
despite not having any ocular manifestations.[27] It
prompts the need for adherence to protective
measures and wearing personal protective
equipment even if no clinical symptoms are
observed.
Episcleral involvement
A case of episcleritis was reported in Spain.
A woman came with cough, myalgia, anosmia,
and ageusia and had a positive PCR result for
COVID-19. After these symptoms were resolved,
she came to the ophthalmologic clinic with
red eye, foreign-body sensation, epiphora,
and photophobia, and nodular episcleritis was
diagnosed. Besides, a study from Turkey revealed
a 2.2% prevalence of episcleritis in COVID-19
patients. It was also shown that episcleritis was
associated with a higher D-dimer level.[25] The
relationship between episcleritis and other viruses
such as Ebola, HBV, HCV, and herpes zoster
and immune-vascular factors and thrombotic
complications of COVID-19 have risen the
suspicion of the role of COVID-19 in developing
episcleritis.[39]
Glaucoma and uveitis
A case of bilateral anterior uveitis following
multisystem inflammatory syndrome in a COVID-
19 patient has been reported so far.[40] In addition,
the involvement of uvea in other animals has been
reported by other coronaviruses.[41, 42]
To the best of our knowledge, no study
has reported glaucoma as a presentation of
COVID-19 yet. However, herpes virus detection
in the trabecular meshwork and the following
trabeculitis can result in intraocular pressure
(IOP) elevation.[43] Cytomegalovirus (CMV)-related
anterior uveitis and the following rise of IOP in
immunocompetent patients have been reported
before, which is accompanied by the detection of
CMV-DNA in aqueous humor.[44–47] Hypertensive
anterior uveitis can present with acute, recurrent,
or chronic symptoms. By knowing the expression
of ACE 2 receptor in aqueous humor[16] and
the role of CMV, herpes simplex virus, and
Ebola virus in developing uveitic glaucoma, we
can hypothesize the possible role of SARS-CoV-
2 in developing, exacerbation, or recurrence of
glaucoma.[43, 44, 48] Therefore, it is not far from
the mind that there will be more reports of
uvea involvement or glaucoma progression in the
future. If so, ophthalmologists should consider
COVID-19 infection in patients with suspicious
symptoms of SARS-CoV-2 and recurrent rise of
IOP.
Ophthalmoparesis and nerve palsy
Dinkin et al reported two cases with
ophthalmoparesis after their COVID-19 PCR
became positive. In the first case, the patient
developed areflexia, third nerve palsy of the
left eye, and sixth nerve palsy of the right eye,
resulting from immune response to the virus or
direct invasion of the virus and the following
demyelination process.[49] The second case
presented with diplopia, abduction deficit, and
optic nerve sheath enhancement of the right eye,
suggesting optic nerve involvement. However,
whether optic nerve involvement resulted
from CNS invasion of the virus or it was only
a coincidence is not clear.[50, 51] In spite of the intact
abducens nerve in MRI, sixth nerve palsy could not
be ruled out in this case.
In Falcone et al’s study, a patient developed
diplopia and abduction deficit three days after the
onset of the respiratory symptoms. MRI findings
showed lateral rectus atrophy and denervation,
all of which favored complete abducens nerve
palsy.[52] Another study revealed bilateral trochlear
nerve palsy in a COVID-19 patient with evidence
of cerebral vasculitis in brain MRI.[53] Overall, all of
the aforementioned cranial nerve involvements can
be the spectrum of neurological manifestations of
COVID-19, caused by either direct involvement of
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Table 1. Characteristics and main findings of the included studies (eyelid, ocular surface, episcleral, uveal, and ocular motor
nerve findings)











Xu[19] April 2020 1 Medium Pain in the lateral
canthus and lower
eyelid swelling
The same as symptoms Tarsadenitis
Megarbane† [20] May 2020 3 High Red eye, painless
eyelid swelling, and
tearing in three cases
Single non-tender
inflammatory nodules in the
middle of the lower eyelid,
conjunctival redness without






















55,924 N/A 0.8% of the patients had
conjunctival congestion
Loffredo[28] April 2020 1,167 Medium Overall rate of conjunctivitis
was 1.1%; 0.7% in non-severe
cases and 3% in severe cases




(3%), dry eye (21%)
and tearing (10.3%)
5% had conjunctival
congestion, 15% of whom as




Navel[30] May 2020 1 Low Follicles, petechias,
tarsal hemorrhages,
and chemosis









the cornea, and subepithelial
infiltrates with overlying
epithelial defects at the
limbus
Keratoconjunctivitis




(21%), epiphora (18.4%), or
increased secretions (18.4%)
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Table 1. Continued)










Sarma[27] April 2020 854 Low 3.2% had conjunctivitis/red
eye, 0.7% reported
conjunctivitis as the first
symptom of the disease. 2%
positive conjunctival/tear
PCR samples
Chen[31] April 2020 1 Low Positivity of conjunctival
swab specimens till 19 days




1 Medium Higher viral load in
late ocular samples
than nasal swabs
Positivity of ocular samples
till 21 days after the disease
onset
Conjunctivitis
Aiello[33] May 2020 252 Medium 12/204 (5.8%) had positive




June 2020 1 Low Red eye, foreign-body
sensation, epiphora,
and photophobia











Bettach[40] June 2020 1 Low Bilateral blurry vision Conjunctival hyperemia,
central corneal edema with
Descemet’s membrane folds,
multiple keratic precipitates,








Case 1: mydriasis, ptosis and
limited depression,
adduction, and abduction
Case 2: enhancement of the
optic nerve sheaths and
posterior Tenon capsules
Case 1: third and sixth
nerve palsy
Case 2: optic nerve
involvement
Falcone[52] June 2020 1 Medium Binocular diplopia Esotropia and limitation of
abduction of the left eye.
Atrophic left lateral rectus
muscle in MRI
Sixth nerve palsy









*The studies are categorized based on the section of the eye involved in a study
†In this study, participants were three nurses working in a COVID-19 ICU but had negative PCR test results
N/A, Not available
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Table 2. Characteristics and main findings of the included studies (retina, neuro–ophthalmology, thromboembolic, and
postmortem findings)











Casagrande[55] May 2020 14 Medium Positivity of retinal biopsy
samples in 3 of 14 (21.4%)
COVID-19 patients
Marinho[56] May 2020 12 High Hyper-reflective lesions in
ganglion cell and inner
plexiform layers more










July 2020 1 High Visually
asymptomatic
Retinal vasculitis on the






July 2020 5 Medium Visually
asymptomatic
Seven out of eight (87.5%)




July 2020 1 Low Reduced sensitivity of
the visual field in left
eye




Raony[62] June 2020 0 N/A Cytokine storm can
aggravate retinal lesions in
infected patients with DM.


























consistent with third nerve
palsy, bilateral sixth nerve
palsy decreased sensation
below the knees to all
modalities
MFS
Kaya[73] April 2020 1 Medium Acute confusional
state, vision loss
MRI showed vasogenic




Doo† [74] July 2020 2 High Visually
asymptomatic
Bilateral posterior cerebral
vasogenic edema in one
case
PRES
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Table 2. Continued)












115 High 30% of COVID-19 patients
with brain MRI had
leukoencephalopathy and/or
cerebral microbleeds
Cariddi[76] June 2020 1 High Blurred vision, altered
mental status
Decreased nasolabial fold,
tone and strength of the legs,
and all deep tendon reflexes
PRES
Parauda† [77] July 2020 4 High Visually
asymptomatic
Imaging showed cerebral
vasogenic edema in four
cases
PRES
Zhou[78] June 2020 1 Medium Bilateral subacute
vision loss of both
eyes. Pain with eye
movements
Bilateral disc edema and
venous congestion. Retinal
perivenous hemorrhages in
the right eye. Positive






Dumitrascu[79] May 2020 1 Medium Sudden onset vision
loss, no light
perception
Retinal and optic disc edema,
retinal exudates, attenuated




Acharya[80] June 2020 1 High Sudden onset vision
loss
Indistinct optic nerve





Casagrande[55] May 2020 14 Medium Mentioned in the Retinal
findings part
Löffler[86] June 2020 3 High Case 1: optic atrophy
Case 2: epiretinal gliosis,
retinal paving-stone and spot
bleeding, and drusen
Case 3: AMD, macular
atrophy, photoreceptor loss
of outer retina, choroid
thinning, and pinguecula
Case 1: MS
Case 2: diabetic and
hypertensive
Case 3: Parkinsonism











chamber fluid, lens, iris,
vitreous, retina, uvea, sclera,
and optic nerve
Fuest[89] July 2020 23 Medium No viral RNA in conjunctival
swabs
*The studies are categorized based on the section of the eye involved in a study
†In these studies, the patients did not have any ophthalmologic findings or symptoms; however, due to the presence of ocular
manifestations in some patients with PRES and leukoencephalopathy, the studies were included
INO, internuclear ophthalmoplegia; GD1b-IgG antibody, antibody against ganglioside complex GD1b; MOG, Myelin
Oligodendrocyte Glycoprotein; PRES, posterior reversible leukoencephalopathy; MFS, Miller Fisher syndrome; N/A, not available
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the CNS, excessive cytokine release, or endothelial
dysfunction.[54]
Retinal findings
A study on retinal biopsies of 14 deceased
patients with COVID-19 showed positivity of
SARS-CoV-2 in three (21%) of them.[55] It is in
line with the expression of ACE 2 receptor in
the human retina.[15] Another study evaluated
retinal findings in COVID-19 patients. It revealed
hyperreflective lesions at the level of ganglion cell
and inner plexiform layers. Besides, four patients
had microhemorrhages and cotton wool spots.
Other ophthalmologic investigations, including
OCT angiography and ganglion cells complex
analysis, visual acuity, and pupillary reflexes,
were normal.[56] Due to the previous reports of
retinitis in animals and these two reports,[57, 58]
the involvement of retina by SARS-CoV-2 is
expectable. Interestingly, a patient was diagnosed
with retinal vasculitis without any ophthalmologic
symptoms.[59] However, because of the absence of
a control group and low sample size in this study,
it is hard to differentiate whether SARS-CoV-2 or
incidental findings cause these findings.
Another study compared OCT findings of optic
nerve before and after COVID-19 infection in
eight eyes of five patients. This study revealed
an overall increase in RNFLT in seven of
eight eyes, which can result from optic nerve
inflammation.[60] Aggravation of retinal lesions in
diabetic retinopathy and papillophlebitis were also
attributed to SARS-CoV-2-induced cytokine storm
and inflammatory process in two studies.[61, 62]
In addition to the direct involvement of the
retina by SARS-CoV-2, COVID-19 can alter the
pattern of some retinal diseases. Studies showed
that COVID-19 lockdown was associated with
less or delayed presentation and diagnosis of
retinal detachment[63] and a higher prevalence of
proliferative vitreoretinopathy, accompanied by a
lower response to surgery.[64, 65] Summaries of the
retinal, neuro-ophthalmologic, thromboembolic,
and postmortem findings are presented in Table 2.
Neuro-ophthalmologic manifestations
Like SARS-CoV, CNS involvement is seen in
COVID-19 infection due to the expression of
ACE2 receptor in nervous tissue and high
affinity of SARS-CoV and SARS-CoV-2 with
this receptor.[66, 67] Guillain-Barré syndrome in
COVID-19 patients has been reported in several
studies.[51, 68, 69] Also, Miller Fisher syndrome, a
variant of Guillain-Barré syndrome presenting with
ophthalmoplegia has been observed in COVID-19
infection.[70, 71] In Gutiérrez-Ortiz et al’s study, the
first patient presented with fascicular oculomotor
palsy and internuclear ophthalmoparesis of
the right eye, and the second patient had
bilateral abducens nerve palsy. Both of them
had albuminocytologic dissociation, areflexia,
and positive oropharyngeal PCR swab test, and
COVID-19 was confirmed. While the first patient
was a Miller Fisher syndrome case, the second was
diagnosed as polyneuritis cranialis.[70] In another
study, a case with a previous history of strabismus
of the left eye presented with left oculomotor nerve
palsy, and after workup, Miller Fisher syndrome
was diagnosed. The nasopharyngeal PCR test
was positive for COVID-19. MRI showed significant
enlargement and enhancement of the third cranial
nerve. Later, the patient manifested with bilateral
abducens nerve palsy.[71]
In another study conducted by Kaya et al, a
38-year-old man was admitted due to COVID-19
developing with sudden onset vision loss. Brain
MRI findings showed vasogenic edema similar to
what is observed in PRES. The exact association
between SARS-CoV-2 and PRES and the etiology
of PRES is not clear in this study. However, due to
the neurotropism of SARS-CoV-2,[72] it is thought
that PRES can be the result of direct invasion of the
virus and the inflammatory process in the setting
of COVID-19 infection.[73] It should be mentioned
that several other studies reported PRES as a rare
presentation of COVID-19, especially in severely
ill patients.[74–77] The severity of vision loss varies
significantly in these studies, ranging from blurred
vision to severe vision loss detecting only hand
motions.
We also found a report of optic neuritis
associated with the Myelin Oligodendrocyte
Glycoprotein (MOG) antibody and COVID-19
infection, which can be another aspect of the
neuro–ophthalmologic manifestations of COVID-
19.[78]
Thromboembolic event
Dumitrascu et al presented the first ocular
vascular complication of COVID-19. A 48-year-old
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obese man with severe COVID-19 infection and
following upper and lower extremities DVTs was
discharged from the hospital. Firstly, enoxaparin
was administered for him, but later, it was changed
to apixaban. One day after the apixaban start,
he developed sudden onset vision loss of right
eye without light perception and obvious relative
afferent pupillary defect. Based on this history and
a funduscopic examination, incomplete ophthalmic
artery occlusion (OAO) was diagnosed.[79] A
case of central retinal artery occlusion was also
reported in a patient with confirmed COVID-19
infection. Interestingly, contrary to the former
case, no previous history of thrombotic events and
anticoagulant consumption were reported for this
patient.[80]
Due to the hypercoagulability state caused by
COVID-19 infection,[81–83] ophthalmologists should
consider SARS-CoV-2 as a possible cause of OAO
in patients with acute vision loss, especially in
ones with underlying hypercoagulability state or
thrombophilia. Also, more studies are needed to
determine the optimal anticoagulant in COVID-19
patients to prevent such complications, especially
in those with a hypercoagulable state.[84, 85]
Post-mortem findings
In Löffler et al’s study, three patients were
evaluated for postmortem ocular findings. The
findings were mainly due to their underlying
diseases and conditions. For example, optic
atrophy was found in a multiple sclerosis patient,
and epiretinal gliosis, retinal paving-stone and
spot bleeding, and drusen were observed in a
diabetic hypertensive case. The third case, a 95-
year-old patient with Parkinsonism, presented with
age-related macular degeneration (AMD), macular
atrophy, photoreceptor loss of the outer retina,
choroid thinning, and pinguecula; in addition,
autolytic changes were seen in microscopic
evaluation of three cases. In another study, three
of 14 retinal samples were positive for SARS-CoV-2
RdRp-gene, E-gene, and Orf nCoV-gene-specific
sequences, which is consistent with the existence
of ACE 2 receptors in human retinal cells.[15, 55, 86]
However, due to the absence of data on examining
these patients before COVID-19 infection, we
cannot ensure that coronavirus did not have any
role in the occurrence or aggravation of these
presentations. Additionally, three other studies
evaluated the SARS-CoV-2 positivity in different
ocular tissues of 29 deceased patients, all of which
were negative.[87–89]
Overall, it seems that there is a low risk of ocular
tissue involvement by SARS-CoV-2. However,
studies with more sample sizes are needed to
confirm this assumption. These findings should
be considered when designing ophthalmology
practice guidelines and criteria for corneal donors
in the COVID-19 era.
Other coronaviruses have been reported to
cause pyogranulomatous anterior uveitis, optic
neuritis, choroiditis with retinal detachment, and
retinal vasculitis in animals.[41, 42] Due to the
presence of ACE 2 receptors in the ciliary body,
vitreous body, and Muller cells,[90, 91] there may
be further reports of the involvement of ocular
structures by SARS-CoV-2 not reported yet. It also
prompts ophthalmologists to remain vigilant about
ocular manifestations of COVID-19. Furthermore,
adhering to eye hygiene principles not only
reduces the risk of SARS-CoV-2 transmission
through the eye, but also reduces the risk of dry
eye, bacterial infections, and the following ocular
disorders.
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